Absolutely spot on - guys dont even worry about the latest pump and dump...the company is a turnaround story in the making. when it gets regulatory approval, we will be looking at a $40-80 mil market cap...especially if market picks up. Its way too cheap at these prices. Load up as much as you can, IMO. DYOR. If it gets regulatory approval, it should be priced as a phase two biotech stock with minimal R&D requirements + the dental business which I'm confident the company will turnaround in the process to become FCF +.
IHL Price at posting:
2.4¢ Sentiment: Buy Disclosure: Held
